Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
Launched by JOHNS HOPKINS UNIVERSITY · Nov 4, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help young people who have received kidney or liver transplants take their anti-rejection medications more consistently. These medications are crucial for preventing the body from rejecting the new organ and avoiding serious health issues like graft loss or even death. To do this, the researchers are using a special electronic pillbox that reminds participants when to take their medication and tracks their doses. If someone forgets, they will receive text message prompts to help them stay on track.
The trial is open to adolescents and young adults aged 13 to 25 who have undergone a kidney or liver transplant at least six months ago and are currently taking specific medications called tacrolimus or sirolimus. Participants will use the electronic pillbox and receive text reminders throughout the study. It's important to note that individuals who are hospitalized, receiving dialysis, or have certain developmental delays cannot participate. This study aims to improve medication adherence, which is vital for the long-term success of their transplant.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment
- • Currently prescribed tacrolimus or sirolimus.
- Exclusion Criteria:
- • Currently receiving dialysis
- • Hospitalized for duration of study
- • Significant developmental or cognitive delay
- • No access to a mobile device that supports text messaging
- • Decline to use electronic pill box to monitor daily medication adherence
- • Non-English speaking
- • If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Cyd Eaton, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials